Cargando…

Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads

Constitutive- and immunoproteasomes are part of the ubiquitin–proteasome system (UPS), which is responsible for the protein homeostasis. Selective inhibition of the immunoproteasome offers opportunities for the treatment of numerous diseases, including inflammation, autoimmune diseases, and hematolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kollár, Levente, Gobec, Martina, Proj, Matic, Smrdel, Lara, Knez, Damijan, Imre, Tímea, Gömöry, Ágnes, Petri, László, Ábrányi-Balogh, Péter, Csányi, Dorottya, Ferenczy, György G., Gobec, Stanislav, Sosič, Izidor, Keserű, György M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700061/
https://www.ncbi.nlm.nih.gov/pubmed/34943940
http://dx.doi.org/10.3390/cells10123431
_version_ 1784620665264930816
author Kollár, Levente
Gobec, Martina
Proj, Matic
Smrdel, Lara
Knez, Damijan
Imre, Tímea
Gömöry, Ágnes
Petri, László
Ábrányi-Balogh, Péter
Csányi, Dorottya
Ferenczy, György G.
Gobec, Stanislav
Sosič, Izidor
Keserű, György M.
author_facet Kollár, Levente
Gobec, Martina
Proj, Matic
Smrdel, Lara
Knez, Damijan
Imre, Tímea
Gömöry, Ágnes
Petri, László
Ábrányi-Balogh, Péter
Csányi, Dorottya
Ferenczy, György G.
Gobec, Stanislav
Sosič, Izidor
Keserű, György M.
author_sort Kollár, Levente
collection PubMed
description Constitutive- and immunoproteasomes are part of the ubiquitin–proteasome system (UPS), which is responsible for the protein homeostasis. Selective inhibition of the immunoproteasome offers opportunities for the treatment of numerous diseases, including inflammation, autoimmune diseases, and hematologic malignancies. Although several inhibitors have been reported, selective nonpeptidic inhibitors are sparse. Here, we describe two series of compounds that target both proteasomes. First, benzoxazole-2-carbonitriles as fragment-sized covalent immunoproteasome inhibitors are reported. Systematic substituent scans around the fragment core of benzoxazole-2-carbonitrile led to compounds with single digit micromolar inhibition of the β5i subunit. Experimental and computational reactivity studies revealed that the substituents do not affect the covalent reactivity of the carbonitrile warhead, but mainly influence the non-covalent recognition. Considering the small size of the inhibitors, this finding emphasizes the importance of the non-covalent recognition step in the covalent mechanism of action. As a follow-up series, bidentate inhibitors are disclosed, in which electrophilic heterocyclic fragments, i.e., 2-vinylthiazole, benzoxazole-2-carbonitrile, and benzimidazole-2-carbonitrile were linked to threonine-targeting (R)-boroleucine moieties. These compounds were designed to bind both the Thr1 and β5i-subunit-specific residue Cys48. However, inhibitory activities against (immuno)proteasome subunits showed that bidentate compounds inhibit the β5, β5i, β1, and β1i subunits with submicromolar to low-micromolar IC(50) values. Inhibitory assays against unrelated enzymes showed that compounds from both series are selective for proteasomes. The presented nonpeptidic and covalent derivatives are suitable hit compounds for the development of either β5i-selective immunoproteasome inhibitors or compounds targeting multiple subunits of both proteasomes.
format Online
Article
Text
id pubmed-8700061
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87000612021-12-24 Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads Kollár, Levente Gobec, Martina Proj, Matic Smrdel, Lara Knez, Damijan Imre, Tímea Gömöry, Ágnes Petri, László Ábrányi-Balogh, Péter Csányi, Dorottya Ferenczy, György G. Gobec, Stanislav Sosič, Izidor Keserű, György M. Cells Article Constitutive- and immunoproteasomes are part of the ubiquitin–proteasome system (UPS), which is responsible for the protein homeostasis. Selective inhibition of the immunoproteasome offers opportunities for the treatment of numerous diseases, including inflammation, autoimmune diseases, and hematologic malignancies. Although several inhibitors have been reported, selective nonpeptidic inhibitors are sparse. Here, we describe two series of compounds that target both proteasomes. First, benzoxazole-2-carbonitriles as fragment-sized covalent immunoproteasome inhibitors are reported. Systematic substituent scans around the fragment core of benzoxazole-2-carbonitrile led to compounds with single digit micromolar inhibition of the β5i subunit. Experimental and computational reactivity studies revealed that the substituents do not affect the covalent reactivity of the carbonitrile warhead, but mainly influence the non-covalent recognition. Considering the small size of the inhibitors, this finding emphasizes the importance of the non-covalent recognition step in the covalent mechanism of action. As a follow-up series, bidentate inhibitors are disclosed, in which electrophilic heterocyclic fragments, i.e., 2-vinylthiazole, benzoxazole-2-carbonitrile, and benzimidazole-2-carbonitrile were linked to threonine-targeting (R)-boroleucine moieties. These compounds were designed to bind both the Thr1 and β5i-subunit-specific residue Cys48. However, inhibitory activities against (immuno)proteasome subunits showed that bidentate compounds inhibit the β5, β5i, β1, and β1i subunits with submicromolar to low-micromolar IC(50) values. Inhibitory assays against unrelated enzymes showed that compounds from both series are selective for proteasomes. The presented nonpeptidic and covalent derivatives are suitable hit compounds for the development of either β5i-selective immunoproteasome inhibitors or compounds targeting multiple subunits of both proteasomes. MDPI 2021-12-06 /pmc/articles/PMC8700061/ /pubmed/34943940 http://dx.doi.org/10.3390/cells10123431 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kollár, Levente
Gobec, Martina
Proj, Matic
Smrdel, Lara
Knez, Damijan
Imre, Tímea
Gömöry, Ágnes
Petri, László
Ábrányi-Balogh, Péter
Csányi, Dorottya
Ferenczy, György G.
Gobec, Stanislav
Sosič, Izidor
Keserű, György M.
Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads
title Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads
title_full Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads
title_fullStr Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads
title_full_unstemmed Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads
title_short Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads
title_sort fragment-sized and bidentate (immuno)proteasome inhibitors derived from cysteine and threonine targeting warheads
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700061/
https://www.ncbi.nlm.nih.gov/pubmed/34943940
http://dx.doi.org/10.3390/cells10123431
work_keys_str_mv AT kollarlevente fragmentsizedandbidentateimmunoproteasomeinhibitorsderivedfromcysteineandthreoninetargetingwarheads
AT gobecmartina fragmentsizedandbidentateimmunoproteasomeinhibitorsderivedfromcysteineandthreoninetargetingwarheads
AT projmatic fragmentsizedandbidentateimmunoproteasomeinhibitorsderivedfromcysteineandthreoninetargetingwarheads
AT smrdellara fragmentsizedandbidentateimmunoproteasomeinhibitorsderivedfromcysteineandthreoninetargetingwarheads
AT knezdamijan fragmentsizedandbidentateimmunoproteasomeinhibitorsderivedfromcysteineandthreoninetargetingwarheads
AT imretimea fragmentsizedandbidentateimmunoproteasomeinhibitorsderivedfromcysteineandthreoninetargetingwarheads
AT gomoryagnes fragmentsizedandbidentateimmunoproteasomeinhibitorsderivedfromcysteineandthreoninetargetingwarheads
AT petrilaszlo fragmentsizedandbidentateimmunoproteasomeinhibitorsderivedfromcysteineandthreoninetargetingwarheads
AT abranyibaloghpeter fragmentsizedandbidentateimmunoproteasomeinhibitorsderivedfromcysteineandthreoninetargetingwarheads
AT csanyidorottya fragmentsizedandbidentateimmunoproteasomeinhibitorsderivedfromcysteineandthreoninetargetingwarheads
AT ferenczygyorgyg fragmentsizedandbidentateimmunoproteasomeinhibitorsderivedfromcysteineandthreoninetargetingwarheads
AT gobecstanislav fragmentsizedandbidentateimmunoproteasomeinhibitorsderivedfromcysteineandthreoninetargetingwarheads
AT sosicizidor fragmentsizedandbidentateimmunoproteasomeinhibitorsderivedfromcysteineandthreoninetargetingwarheads
AT keserugyorgym fragmentsizedandbidentateimmunoproteasomeinhibitorsderivedfromcysteineandthreoninetargetingwarheads